Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine

Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine

Oct 03, 2020
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-announces-five-year-data-reinforce-safety-and-efficacy-profile-aimovig-erenumab-aooe-adult-patients-episodic-migraine-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-announces-five-year-data-reinforce-safety-and-efficacy-profile-aimovig-erenumab-aooe-adult-patients-episodic-migraine-0